Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration
To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A phase IIb, randomized, multicenter, double-maske...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology retina 2023-07, Vol.7 (7), p.573-585 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 585 |
|---|---|
| container_issue | 7 |
| container_start_page | 573 |
| container_title | Ophthalmology retina |
| container_volume | 7 |
| creator | Freeman, William R. Bandello, Francesco Souied, Eric Guymer, Robyn H. Garg, Sunir J. Chen, Fred K. Rich, Ryan Holz, Frank G. Patel, Sunil S. Kim, Kimmie López, Francisco J. Chen, Fred Guymer, Robyn Korobelnik, Jean-Francois Souied, Eric Holz, Frank Ziemssen, Focke Bandello, Francesco Campos, Emilio GrignoloEandi, Chiara Midena, Edoardo Peiretti, Enrico Staurenghi, Giovanni Viola, Francesco Bailey, Clare Esposti, Simona Degli Jackson, Timothy Menon, Geeta Pagliarini, Sergio Quhill, Fahd Antoszyk, Andrew Brooks, Logan Callanan, David Csaky, Karl Edwards, Albert Eichenbaum, David Freeman, William Garg, Sunir Ghuman, Avtar Thomas Gonzalez, Victor Gupta, Sunil Hamilton, Richard Khurana, Rahul Kunimoto, Derek Kuppermann, Baruch Lauer, Andreas Lee, Seong Young Maturi, Raj Patel, Sunil Reddy, Rahul Rich, Ryan Rivellese, Mark Rose, Steven Segal, Zachary Wong, Robert |
| description | To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
A phase IIb, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON).
Patients diagnosed with GA secondary to AMD and multifocal lesions with total area of > 1.25 mm2 and ≤ 18 mm2 in the study eye.
Enrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n = 154) or sham procedure (n = 156) in the study eye every 3 months from day 1 to month 21.
The primary efficacy endpoint was GA lesion area change from baseline in the study eye, assessed with fundus autofluorescence imaging, at month 24.
The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼ 1.6 mm2/year) in the enrolled population. Least squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm2 with Brimo DDS (n = 84) versus 3.48 (0.13) mm2 with sham (n = 91), a reduction of 0.25 mm2 (7%) with Brimo DDS compared with sham (P = 0.150). At month 30, GA area change from baseline was 4.09 (0.15) mm2 with Brimo DDS (n = 49) versus 4.52 (0.15) mm2 with sham (n = 46), a reduction of 0.43 mm2 (10%) with Brimo DDS compared with sham (P = 0.033). Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24). Treatment-related adverse events were usually related to the injection procedure. No implant accumulation was observed.
Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. The primary efficacy endpoint at 24 months was not met, but there was a numeric trend for reduction in GA progression at 24 months compared with sham treatment. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group.
Proprietary or commercial disclosures may be found after the references. |
| doi_str_mv | 10.1016/j.oret.2023.03.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2786098290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2468653023000970</els_id><sourcerecordid>2786098290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-4f848ab2a1f073bff7fd1fd025eeb1ed50eae2796b857b0ca1d0f6e4256d1f493</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EolXpC3BAPnLJMnYSJ5G4LC2UlYpALZwtxx7vepXEi-1UCg_Ac-PVlooT0kgzsr7_H3l-Ql4zWDFg4t1-5QOmFQderiAXsGfknFeiLURdwvN_5jNyGeMeMtFyIRp4Sc5K0YFgTXNOft-pyfjR_UJDv-1URLrZ9PQ-zWah3tIPwY1-csZNSK_DvKXXOLgHDAu9X2LCkd7ghEEl5yfKqfUhP_htUIed03Sdgj_sFuomut5icYeDSnnNF6XnQYVstX0SvyIvrBoiXj72C_Lj08fvV5-L2683m6v1baErgFRUtq1a1XPFLDRlb21jDbMGeI3YMzQ1oELedKJv66YHrZgBK7Ditchc1ZUX5O3J9xD8zxljkqOLGodBTejnKHnTCuha3kFG-QnVwccY0MpDPoYKi2QgjxHIvTxGII8RSMgFLIvePPrP_YjmSfL34Bl4fwIw__LBYZBRO5w0GhdQJ2m8-5__H7-GmTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786098290</pqid></control><display><type>article</type><title>Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Freeman, William R. ; Bandello, Francesco ; Souied, Eric ; Guymer, Robyn H. ; Garg, Sunir J. ; Chen, Fred K. ; Rich, Ryan ; Holz, Frank G. ; Patel, Sunil S. ; Kim, Kimmie ; López, Francisco J. ; Chen, Fred ; Guymer, Robyn ; Korobelnik, Jean-Francois ; Souied, Eric ; Holz, Frank ; Ziemssen, Focke ; Bandello, Francesco ; Campos, Emilio ; GrignoloEandi, Chiara ; Midena, Edoardo ; Peiretti, Enrico ; Staurenghi, Giovanni ; Viola, Francesco ; Bailey, Clare ; Esposti, Simona Degli ; Jackson, Timothy ; Menon, Geeta ; Pagliarini, Sergio ; Quhill, Fahd ; Antoszyk, Andrew ; Brooks, Logan ; Callanan, David ; Csaky, Karl ; Edwards, Albert ; Eichenbaum, David ; Freeman, William ; Garg, Sunir ; Ghuman, Avtar Thomas ; Gonzalez, Victor ; Gupta, Sunil ; Hamilton, Richard ; Khurana, Rahul ; Kunimoto, Derek ; Kuppermann, Baruch ; Lauer, Andreas ; Lee, Seong Young ; Maturi, Raj ; Patel, Sunil ; Reddy, Rahul ; Rich, Ryan ; Rivellese, Mark ; Rose, Steven ; Segal, Zachary ; Wong, Robert</creator><creatorcontrib>Freeman, William R. ; Bandello, Francesco ; Souied, Eric ; Guymer, Robyn H. ; Garg, Sunir J. ; Chen, Fred K. ; Rich, Ryan ; Holz, Frank G. ; Patel, Sunil S. ; Kim, Kimmie ; López, Francisco J. ; Chen, Fred ; Guymer, Robyn ; Korobelnik, Jean-Francois ; Souied, Eric ; Holz, Frank ; Ziemssen, Focke ; Bandello, Francesco ; Campos, Emilio ; GrignoloEandi, Chiara ; Midena, Edoardo ; Peiretti, Enrico ; Staurenghi, Giovanni ; Viola, Francesco ; Bailey, Clare ; Esposti, Simona Degli ; Jackson, Timothy ; Menon, Geeta ; Pagliarini, Sergio ; Quhill, Fahd ; Antoszyk, Andrew ; Brooks, Logan ; Callanan, David ; Csaky, Karl ; Edwards, Albert ; Eichenbaum, David ; Freeman, William ; Garg, Sunir ; Ghuman, Avtar Thomas ; Gonzalez, Victor ; Gupta, Sunil ; Hamilton, Richard ; Khurana, Rahul ; Kunimoto, Derek ; Kuppermann, Baruch ; Lauer, Andreas ; Lee, Seong Young ; Maturi, Raj ; Patel, Sunil ; Reddy, Rahul ; Rich, Ryan ; Rivellese, Mark ; Rose, Steven ; Segal, Zachary ; Wong, Robert ; BEACON Study Group</creatorcontrib><description>To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
A phase IIb, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON).
Patients diagnosed with GA secondary to AMD and multifocal lesions with total area of > 1.25 mm2 and ≤ 18 mm2 in the study eye.
Enrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n = 154) or sham procedure (n = 156) in the study eye every 3 months from day 1 to month 21.
The primary efficacy endpoint was GA lesion area change from baseline in the study eye, assessed with fundus autofluorescence imaging, at month 24.
The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼ 1.6 mm2/year) in the enrolled population. Least squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm2 with Brimo DDS (n = 84) versus 3.48 (0.13) mm2 with sham (n = 91), a reduction of 0.25 mm2 (7%) with Brimo DDS compared with sham (P = 0.150). At month 30, GA area change from baseline was 4.09 (0.15) mm2 with Brimo DDS (n = 49) versus 4.52 (0.15) mm2 with sham (n = 46), a reduction of 0.43 mm2 (10%) with Brimo DDS compared with sham (P = 0.033). Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24). Treatment-related adverse events were usually related to the injection procedure. No implant accumulation was observed.
Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. The primary efficacy endpoint at 24 months was not met, but there was a numeric trend for reduction in GA progression at 24 months compared with sham treatment. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group.
Proprietary or commercial disclosures may be found after the references.</description><identifier>ISSN: 2468-6530</identifier><identifier>EISSN: 2468-6530</identifier><identifier>DOI: 10.1016/j.oret.2023.03.001</identifier><identifier>PMID: 36906177</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age-related macular degeneration ; Brimonidine ; Drug Delivery Systems - adverse effects ; Geographic atrophy ; Geographic Atrophy - diagnosis ; Geographic Atrophy - drug therapy ; Geographic Atrophy - etiology ; Humans ; Implant ; Intravitreal Injections ; Macular Degeneration - complications ; Macular Degeneration - diagnosis ; Macular Degeneration - drug therapy ; Nonexudative ; Retina</subject><ispartof>Ophthalmology retina, 2023-07, Vol.7 (7), p.573-585</ispartof><rights>2023 American Academy of Ophthalmology</rights><rights>Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-4f848ab2a1f073bff7fd1fd025eeb1ed50eae2796b857b0ca1d0f6e4256d1f493</citedby><cites>FETCH-LOGICAL-c400t-4f848ab2a1f073bff7fd1fd025eeb1ed50eae2796b857b0ca1d0f6e4256d1f493</cites><orcidid>0000-0002-0511-4942 ; 0000-0003-3238-9682 ; 0000-0002-9441-4356 ; 0000-0003-0189-861X ; 0000-0003-2809-9930</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36906177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freeman, William R.</creatorcontrib><creatorcontrib>Bandello, Francesco</creatorcontrib><creatorcontrib>Souied, Eric</creatorcontrib><creatorcontrib>Guymer, Robyn H.</creatorcontrib><creatorcontrib>Garg, Sunir J.</creatorcontrib><creatorcontrib>Chen, Fred K.</creatorcontrib><creatorcontrib>Rich, Ryan</creatorcontrib><creatorcontrib>Holz, Frank G.</creatorcontrib><creatorcontrib>Patel, Sunil S.</creatorcontrib><creatorcontrib>Kim, Kimmie</creatorcontrib><creatorcontrib>López, Francisco J.</creatorcontrib><creatorcontrib>Chen, Fred</creatorcontrib><creatorcontrib>Guymer, Robyn</creatorcontrib><creatorcontrib>Korobelnik, Jean-Francois</creatorcontrib><creatorcontrib>Souied, Eric</creatorcontrib><creatorcontrib>Holz, Frank</creatorcontrib><creatorcontrib>Ziemssen, Focke</creatorcontrib><creatorcontrib>Bandello, Francesco</creatorcontrib><creatorcontrib>Campos, Emilio</creatorcontrib><creatorcontrib>GrignoloEandi, Chiara</creatorcontrib><creatorcontrib>Midena, Edoardo</creatorcontrib><creatorcontrib>Peiretti, Enrico</creatorcontrib><creatorcontrib>Staurenghi, Giovanni</creatorcontrib><creatorcontrib>Viola, Francesco</creatorcontrib><creatorcontrib>Bailey, Clare</creatorcontrib><creatorcontrib>Esposti, Simona Degli</creatorcontrib><creatorcontrib>Jackson, Timothy</creatorcontrib><creatorcontrib>Menon, Geeta</creatorcontrib><creatorcontrib>Pagliarini, Sergio</creatorcontrib><creatorcontrib>Quhill, Fahd</creatorcontrib><creatorcontrib>Antoszyk, Andrew</creatorcontrib><creatorcontrib>Brooks, Logan</creatorcontrib><creatorcontrib>Callanan, David</creatorcontrib><creatorcontrib>Csaky, Karl</creatorcontrib><creatorcontrib>Edwards, Albert</creatorcontrib><creatorcontrib>Eichenbaum, David</creatorcontrib><creatorcontrib>Freeman, William</creatorcontrib><creatorcontrib>Garg, Sunir</creatorcontrib><creatorcontrib>Ghuman, Avtar Thomas</creatorcontrib><creatorcontrib>Gonzalez, Victor</creatorcontrib><creatorcontrib>Gupta, Sunil</creatorcontrib><creatorcontrib>Hamilton, Richard</creatorcontrib><creatorcontrib>Khurana, Rahul</creatorcontrib><creatorcontrib>Kunimoto, Derek</creatorcontrib><creatorcontrib>Kuppermann, Baruch</creatorcontrib><creatorcontrib>Lauer, Andreas</creatorcontrib><creatorcontrib>Lee, Seong Young</creatorcontrib><creatorcontrib>Maturi, Raj</creatorcontrib><creatorcontrib>Patel, Sunil</creatorcontrib><creatorcontrib>Reddy, Rahul</creatorcontrib><creatorcontrib>Rich, Ryan</creatorcontrib><creatorcontrib>Rivellese, Mark</creatorcontrib><creatorcontrib>Rose, Steven</creatorcontrib><creatorcontrib>Segal, Zachary</creatorcontrib><creatorcontrib>Wong, Robert</creatorcontrib><creatorcontrib>BEACON Study Group</creatorcontrib><title>Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration</title><title>Ophthalmology retina</title><addtitle>Ophthalmol Retina</addtitle><description>To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
A phase IIb, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON).
Patients diagnosed with GA secondary to AMD and multifocal lesions with total area of > 1.25 mm2 and ≤ 18 mm2 in the study eye.
Enrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n = 154) or sham procedure (n = 156) in the study eye every 3 months from day 1 to month 21.
The primary efficacy endpoint was GA lesion area change from baseline in the study eye, assessed with fundus autofluorescence imaging, at month 24.
The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼ 1.6 mm2/year) in the enrolled population. Least squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm2 with Brimo DDS (n = 84) versus 3.48 (0.13) mm2 with sham (n = 91), a reduction of 0.25 mm2 (7%) with Brimo DDS compared with sham (P = 0.150). At month 30, GA area change from baseline was 4.09 (0.15) mm2 with Brimo DDS (n = 49) versus 4.52 (0.15) mm2 with sham (n = 46), a reduction of 0.43 mm2 (10%) with Brimo DDS compared with sham (P = 0.033). Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24). Treatment-related adverse events were usually related to the injection procedure. No implant accumulation was observed.
Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. The primary efficacy endpoint at 24 months was not met, but there was a numeric trend for reduction in GA progression at 24 months compared with sham treatment. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group.
Proprietary or commercial disclosures may be found after the references.</description><subject>Age-related macular degeneration</subject><subject>Brimonidine</subject><subject>Drug Delivery Systems - adverse effects</subject><subject>Geographic atrophy</subject><subject>Geographic Atrophy - diagnosis</subject><subject>Geographic Atrophy - drug therapy</subject><subject>Geographic Atrophy - etiology</subject><subject>Humans</subject><subject>Implant</subject><subject>Intravitreal Injections</subject><subject>Macular Degeneration - complications</subject><subject>Macular Degeneration - diagnosis</subject><subject>Macular Degeneration - drug therapy</subject><subject>Nonexudative</subject><subject>Retina</subject><issn>2468-6530</issn><issn>2468-6530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EolXpC3BAPnLJMnYSJ5G4LC2UlYpALZwtxx7vepXEi-1UCg_Ac-PVlooT0kgzsr7_H3l-Ql4zWDFg4t1-5QOmFQderiAXsGfknFeiLURdwvN_5jNyGeMeMtFyIRp4Sc5K0YFgTXNOft-pyfjR_UJDv-1URLrZ9PQ-zWah3tIPwY1-csZNSK_DvKXXOLgHDAu9X2LCkd7ghEEl5yfKqfUhP_htUIed03Sdgj_sFuomut5icYeDSnnNF6XnQYVstX0SvyIvrBoiXj72C_Lj08fvV5-L2683m6v1baErgFRUtq1a1XPFLDRlb21jDbMGeI3YMzQ1oELedKJv66YHrZgBK7Ditchc1ZUX5O3J9xD8zxljkqOLGodBTejnKHnTCuha3kFG-QnVwccY0MpDPoYKi2QgjxHIvTxGII8RSMgFLIvePPrP_YjmSfL34Bl4fwIw__LBYZBRO5w0GhdQJ2m8-5__H7-GmTQ</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Freeman, William R.</creator><creator>Bandello, Francesco</creator><creator>Souied, Eric</creator><creator>Guymer, Robyn H.</creator><creator>Garg, Sunir J.</creator><creator>Chen, Fred K.</creator><creator>Rich, Ryan</creator><creator>Holz, Frank G.</creator><creator>Patel, Sunil S.</creator><creator>Kim, Kimmie</creator><creator>López, Francisco J.</creator><creator>Chen, Fred</creator><creator>Guymer, Robyn</creator><creator>Korobelnik, Jean-Francois</creator><creator>Souied, Eric</creator><creator>Holz, Frank</creator><creator>Ziemssen, Focke</creator><creator>Bandello, Francesco</creator><creator>Campos, Emilio</creator><creator>GrignoloEandi, Chiara</creator><creator>Midena, Edoardo</creator><creator>Peiretti, Enrico</creator><creator>Staurenghi, Giovanni</creator><creator>Viola, Francesco</creator><creator>Bailey, Clare</creator><creator>Esposti, Simona Degli</creator><creator>Jackson, Timothy</creator><creator>Menon, Geeta</creator><creator>Pagliarini, Sergio</creator><creator>Quhill, Fahd</creator><creator>Antoszyk, Andrew</creator><creator>Brooks, Logan</creator><creator>Callanan, David</creator><creator>Csaky, Karl</creator><creator>Edwards, Albert</creator><creator>Eichenbaum, David</creator><creator>Freeman, William</creator><creator>Garg, Sunir</creator><creator>Ghuman, Avtar Thomas</creator><creator>Gonzalez, Victor</creator><creator>Gupta, Sunil</creator><creator>Hamilton, Richard</creator><creator>Khurana, Rahul</creator><creator>Kunimoto, Derek</creator><creator>Kuppermann, Baruch</creator><creator>Lauer, Andreas</creator><creator>Lee, Seong Young</creator><creator>Maturi, Raj</creator><creator>Patel, Sunil</creator><creator>Reddy, Rahul</creator><creator>Rich, Ryan</creator><creator>Rivellese, Mark</creator><creator>Rose, Steven</creator><creator>Segal, Zachary</creator><creator>Wong, Robert</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0511-4942</orcidid><orcidid>https://orcid.org/0000-0003-3238-9682</orcidid><orcidid>https://orcid.org/0000-0002-9441-4356</orcidid><orcidid>https://orcid.org/0000-0003-0189-861X</orcidid><orcidid>https://orcid.org/0000-0003-2809-9930</orcidid></search><sort><creationdate>202307</creationdate><title>Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration</title><author>Freeman, William R. ; Bandello, Francesco ; Souied, Eric ; Guymer, Robyn H. ; Garg, Sunir J. ; Chen, Fred K. ; Rich, Ryan ; Holz, Frank G. ; Patel, Sunil S. ; Kim, Kimmie ; López, Francisco J. ; Chen, Fred ; Guymer, Robyn ; Korobelnik, Jean-Francois ; Souied, Eric ; Holz, Frank ; Ziemssen, Focke ; Bandello, Francesco ; Campos, Emilio ; GrignoloEandi, Chiara ; Midena, Edoardo ; Peiretti, Enrico ; Staurenghi, Giovanni ; Viola, Francesco ; Bailey, Clare ; Esposti, Simona Degli ; Jackson, Timothy ; Menon, Geeta ; Pagliarini, Sergio ; Quhill, Fahd ; Antoszyk, Andrew ; Brooks, Logan ; Callanan, David ; Csaky, Karl ; Edwards, Albert ; Eichenbaum, David ; Freeman, William ; Garg, Sunir ; Ghuman, Avtar Thomas ; Gonzalez, Victor ; Gupta, Sunil ; Hamilton, Richard ; Khurana, Rahul ; Kunimoto, Derek ; Kuppermann, Baruch ; Lauer, Andreas ; Lee, Seong Young ; Maturi, Raj ; Patel, Sunil ; Reddy, Rahul ; Rich, Ryan ; Rivellese, Mark ; Rose, Steven ; Segal, Zachary ; Wong, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-4f848ab2a1f073bff7fd1fd025eeb1ed50eae2796b857b0ca1d0f6e4256d1f493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age-related macular degeneration</topic><topic>Brimonidine</topic><topic>Drug Delivery Systems - adverse effects</topic><topic>Geographic atrophy</topic><topic>Geographic Atrophy - diagnosis</topic><topic>Geographic Atrophy - drug therapy</topic><topic>Geographic Atrophy - etiology</topic><topic>Humans</topic><topic>Implant</topic><topic>Intravitreal Injections</topic><topic>Macular Degeneration - complications</topic><topic>Macular Degeneration - diagnosis</topic><topic>Macular Degeneration - drug therapy</topic><topic>Nonexudative</topic><topic>Retina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freeman, William R.</creatorcontrib><creatorcontrib>Bandello, Francesco</creatorcontrib><creatorcontrib>Souied, Eric</creatorcontrib><creatorcontrib>Guymer, Robyn H.</creatorcontrib><creatorcontrib>Garg, Sunir J.</creatorcontrib><creatorcontrib>Chen, Fred K.</creatorcontrib><creatorcontrib>Rich, Ryan</creatorcontrib><creatorcontrib>Holz, Frank G.</creatorcontrib><creatorcontrib>Patel, Sunil S.</creatorcontrib><creatorcontrib>Kim, Kimmie</creatorcontrib><creatorcontrib>López, Francisco J.</creatorcontrib><creatorcontrib>Chen, Fred</creatorcontrib><creatorcontrib>Guymer, Robyn</creatorcontrib><creatorcontrib>Korobelnik, Jean-Francois</creatorcontrib><creatorcontrib>Souied, Eric</creatorcontrib><creatorcontrib>Holz, Frank</creatorcontrib><creatorcontrib>Ziemssen, Focke</creatorcontrib><creatorcontrib>Bandello, Francesco</creatorcontrib><creatorcontrib>Campos, Emilio</creatorcontrib><creatorcontrib>GrignoloEandi, Chiara</creatorcontrib><creatorcontrib>Midena, Edoardo</creatorcontrib><creatorcontrib>Peiretti, Enrico</creatorcontrib><creatorcontrib>Staurenghi, Giovanni</creatorcontrib><creatorcontrib>Viola, Francesco</creatorcontrib><creatorcontrib>Bailey, Clare</creatorcontrib><creatorcontrib>Esposti, Simona Degli</creatorcontrib><creatorcontrib>Jackson, Timothy</creatorcontrib><creatorcontrib>Menon, Geeta</creatorcontrib><creatorcontrib>Pagliarini, Sergio</creatorcontrib><creatorcontrib>Quhill, Fahd</creatorcontrib><creatorcontrib>Antoszyk, Andrew</creatorcontrib><creatorcontrib>Brooks, Logan</creatorcontrib><creatorcontrib>Callanan, David</creatorcontrib><creatorcontrib>Csaky, Karl</creatorcontrib><creatorcontrib>Edwards, Albert</creatorcontrib><creatorcontrib>Eichenbaum, David</creatorcontrib><creatorcontrib>Freeman, William</creatorcontrib><creatorcontrib>Garg, Sunir</creatorcontrib><creatorcontrib>Ghuman, Avtar Thomas</creatorcontrib><creatorcontrib>Gonzalez, Victor</creatorcontrib><creatorcontrib>Gupta, Sunil</creatorcontrib><creatorcontrib>Hamilton, Richard</creatorcontrib><creatorcontrib>Khurana, Rahul</creatorcontrib><creatorcontrib>Kunimoto, Derek</creatorcontrib><creatorcontrib>Kuppermann, Baruch</creatorcontrib><creatorcontrib>Lauer, Andreas</creatorcontrib><creatorcontrib>Lee, Seong Young</creatorcontrib><creatorcontrib>Maturi, Raj</creatorcontrib><creatorcontrib>Patel, Sunil</creatorcontrib><creatorcontrib>Reddy, Rahul</creatorcontrib><creatorcontrib>Rich, Ryan</creatorcontrib><creatorcontrib>Rivellese, Mark</creatorcontrib><creatorcontrib>Rose, Steven</creatorcontrib><creatorcontrib>Segal, Zachary</creatorcontrib><creatorcontrib>Wong, Robert</creatorcontrib><creatorcontrib>BEACON Study Group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology retina</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freeman, William R.</au><au>Bandello, Francesco</au><au>Souied, Eric</au><au>Guymer, Robyn H.</au><au>Garg, Sunir J.</au><au>Chen, Fred K.</au><au>Rich, Ryan</au><au>Holz, Frank G.</au><au>Patel, Sunil S.</au><au>Kim, Kimmie</au><au>López, Francisco J.</au><au>Chen, Fred</au><au>Guymer, Robyn</au><au>Korobelnik, Jean-Francois</au><au>Souied, Eric</au><au>Holz, Frank</au><au>Ziemssen, Focke</au><au>Bandello, Francesco</au><au>Campos, Emilio</au><au>GrignoloEandi, Chiara</au><au>Midena, Edoardo</au><au>Peiretti, Enrico</au><au>Staurenghi, Giovanni</au><au>Viola, Francesco</au><au>Bailey, Clare</au><au>Esposti, Simona Degli</au><au>Jackson, Timothy</au><au>Menon, Geeta</au><au>Pagliarini, Sergio</au><au>Quhill, Fahd</au><au>Antoszyk, Andrew</au><au>Brooks, Logan</au><au>Callanan, David</au><au>Csaky, Karl</au><au>Edwards, Albert</au><au>Eichenbaum, David</au><au>Freeman, William</au><au>Garg, Sunir</au><au>Ghuman, Avtar Thomas</au><au>Gonzalez, Victor</au><au>Gupta, Sunil</au><au>Hamilton, Richard</au><au>Khurana, Rahul</au><au>Kunimoto, Derek</au><au>Kuppermann, Baruch</au><au>Lauer, Andreas</au><au>Lee, Seong Young</au><au>Maturi, Raj</au><au>Patel, Sunil</au><au>Reddy, Rahul</au><au>Rich, Ryan</au><au>Rivellese, Mark</au><au>Rose, Steven</au><au>Segal, Zachary</au><au>Wong, Robert</au><aucorp>BEACON Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration</atitle><jtitle>Ophthalmology retina</jtitle><addtitle>Ophthalmol Retina</addtitle><date>2023-07</date><risdate>2023</risdate><volume>7</volume><issue>7</issue><spage>573</spage><epage>585</epage><pages>573-585</pages><issn>2468-6530</issn><eissn>2468-6530</eissn><abstract>To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
A phase IIb, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON).
Patients diagnosed with GA secondary to AMD and multifocal lesions with total area of > 1.25 mm2 and ≤ 18 mm2 in the study eye.
Enrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n = 154) or sham procedure (n = 156) in the study eye every 3 months from day 1 to month 21.
The primary efficacy endpoint was GA lesion area change from baseline in the study eye, assessed with fundus autofluorescence imaging, at month 24.
The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼ 1.6 mm2/year) in the enrolled population. Least squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm2 with Brimo DDS (n = 84) versus 3.48 (0.13) mm2 with sham (n = 91), a reduction of 0.25 mm2 (7%) with Brimo DDS compared with sham (P = 0.150). At month 30, GA area change from baseline was 4.09 (0.15) mm2 with Brimo DDS (n = 49) versus 4.52 (0.15) mm2 with sham (n = 46), a reduction of 0.43 mm2 (10%) with Brimo DDS compared with sham (P = 0.033). Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS than with sham (P = 0.053 at month 24). Treatment-related adverse events were usually related to the injection procedure. No implant accumulation was observed.
Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. The primary efficacy endpoint at 24 months was not met, but there was a numeric trend for reduction in GA progression at 24 months compared with sham treatment. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group.
Proprietary or commercial disclosures may be found after the references.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36906177</pmid><doi>10.1016/j.oret.2023.03.001</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-0511-4942</orcidid><orcidid>https://orcid.org/0000-0003-3238-9682</orcidid><orcidid>https://orcid.org/0000-0002-9441-4356</orcidid><orcidid>https://orcid.org/0000-0003-0189-861X</orcidid><orcidid>https://orcid.org/0000-0003-2809-9930</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2468-6530 |
| ispartof | Ophthalmology retina, 2023-07, Vol.7 (7), p.573-585 |
| issn | 2468-6530 2468-6530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2786098290 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Age-related macular degeneration Brimonidine Drug Delivery Systems - adverse effects Geographic atrophy Geographic Atrophy - diagnosis Geographic Atrophy - drug therapy Geographic Atrophy - etiology Humans Implant Intravitreal Injections Macular Degeneration - complications Macular Degeneration - diagnosis Macular Degeneration - drug therapy Nonexudative Retina |
| title | Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A13%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20Phase%20IIb%20Study%20of%20Brimonidine%20Drug%20Delivery%20System%20Generation%202%20for%20Geographic%20Atrophy%20in%20Age-Related%20Macular%20Degeneration&rft.jtitle=Ophthalmology%20retina&rft.au=Freeman,%20William%20R.&rft.aucorp=BEACON%20Study%20Group&rft.date=2023-07&rft.volume=7&rft.issue=7&rft.spage=573&rft.epage=585&rft.pages=573-585&rft.issn=2468-6530&rft.eissn=2468-6530&rft_id=info:doi/10.1016/j.oret.2023.03.001&rft_dat=%3Cproquest_cross%3E2786098290%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786098290&rft_id=info:pmid/36906177&rft_els_id=S2468653023000970&rfr_iscdi=true |